Presynaptic dopaminergic pathology in Chediak-Higashi syndrome with parkinsonian syndrome.
Jacobi
C
C
Department of Neurology, University of Heidelberg, Heidelberg, Germany. christian_jacobi@med.uni-heidelberg.de
Koerner
C
C
Fruehauf
S
S
Rottenburger
C
C
Storch-Hagenlocher
B
B
Grau
A J
AJ
D000328:Adult; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002609:Chediak-Higashi Syndrome / Q000150:complications / Q000000981:diagnostic imaging* / Q000503:physiopathology*; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D007962:Leukocytes / Q000201:enzymology / Q000473:pathology; D008297:Male; D017072:Neostriatum / Q000000981:diagnostic imaging* / Q000503:physiopathology; D009434:Neural Pathways / Q000503:physiopathology; D020734:Parkinsonian Disorders / Q000150:complications / Q000000981:diagnostic imaging* / Q000503:physiopathology; D017729:Presynaptic Terminals / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D013378:Substantia Nigra / Q000000981:diagnostic imaging* / Q000503:physiopathology; D009435:Synaptic Transmission / Q000235:genetics; D015899:Tomography, Emission-Computed, Single-Photon; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D004298:Dopamine